Varian Medical Systems, Inc. has received an FDA 510(k) clearance for the latest version of its Vitesse(TM) real time planning for HDR brachytherapy which is used to plan and perform high-dose-rate (HDR), ultrasound-guided brachytherapy treatments for prostate cancer. HDR brachytherapy involves delivering radiotherapy from inside the body by temporarily placing a tiny radioactive source directly into the tumor or other targeted area. Using a robotic device called an afterloader, clinicians place the radioactive source into positions through needles that have been inserted into the area being treated.

The source is then moved within the needles under computer control to create the specified dose distribution within the patient's anatomy. Using the latest version of Vitesse, HDR brachytherapy treatment plans can be created in a real-time environment, using ultrasound images generated in the operating room rather than CT scans generated elsewhere. This avoids the need to move the patient to a CT scanner room for imaging after the needles have been put in place.

The process can now be completed entirely within the Vitesse program, from capturing the ultrasound image to finalizing an approved treatment plan. In addition to receiving FDA 510(k) clearance which permits sale of the Vitesse software in the United States, Varian has also obtained the CE Mark which permits sales in the European Union and other countries where the CE Mark is recognized.